Best Life Sciences Companies in United Kingdom

#1

Isomorphic Labs Series B

location_onLondon, England

Digital platform focused on revolutionizing drug discovery using AI. The company's computational tools analyze complex biological phenomena to assist in the design of molecules. The technology predicts how potential therapeutic compounds perform to facilitate the development of treatments for various diseases.

#2

CellCentric Series D

location_onCambridge, England

Developer of oral small molecule inhibitors for treating blood cancers. This pharmaceutical entity focuses on creating therapeutic agents that target specific proteins involved in tumor progression. The research involves modulating gene expression by disrupting the interaction of transcription co-activation factors within cancer cells. The primary therapeutic candidate is designed to address multiple myeloma and othe

#3

STORM Therapeutics Series C

location_onWaterbeach, Cambridgeshire

Developer of small molecule inhibitors targeting enzymes that modify RNA. These therapeutic agents focus on regulating protein synthesis by modulating the activity of enzymes involved in ribonucleic acid modification. The research and development efforts center on clinical applications for treating various forms of cancer. By targeting specific biological pathways, these inhibitors aim to influence cellular decision-

#4

Enterobiotix Series B

location_onEdinburgh, Scotland

Developer of microbiome-based therapeutics for multiple disease targets. The company is engaged in developing an integrated anaerobic system which comprises of a closed system collection and processing benchtop system that will allow therapies to be produced outside of cleanrooms and in anaerobic environments. It aims to offer microbiome therapy to patients suffering from Inflammatory Bowel Disease and other diseases

#5

Cytospire Therapeutics Series A

location_onLondon, England

Provider of immune cell engagers for treating cancer. It offers a portfolio of differentiated multispecific engager antibodies to enhance and direct the activity of innate and adaptive effector immune cells to discriminate between target diseased vs healthy cell for the treatment of solid tumors and other cancer.

#6

Bit.bio Series C

location_onCambridge, England

Manufacturer of programmed human cells for research and drug discovery. This entity utilizes gene-targeting technology to express transcription factors that reprogram induced pluripotent stem cells into defined human cell types. These products include various nerve, immune, and muscle cell lines designed for use in laboratory assays, disease modeling, and therapeutic development. The technology enables the production

#7

Lightcast Series B

location_onCambridge, England

Developer of single-cell functional analysis using a droplet-based platform. The technology uses light rays to precisely control picoliter-scale droplets, enabling scalable assays for drug discovery, therapeutics, and basic research. The system facilitates sequential assays and the real-time dispensing of cells for downstream applications. It supports research into biomolecule secretion, cell-cell communication, and

#8

Automata Series C

location_onLondon, England

Developer of modular lab automation platforms for biological research workflows. This system integrates hardware and software to orchestrate laboratory processes, including sample handling and instrument management. The platform utilizes node-based design tools and software development kits to enable workflow configuration and simulation. It supports connectivity with external data systems and analytical models to fa

#9

Artios Series D

location_onCambridge, England

Developer of therapeutics targeting the deoxyribonucleic acid damage response in cancer. These treatments focus on inhibiting specific enzymes involved in cellular repair mechanisms to induce damage within malignant tissues. The approach utilizes small-molecule inhibitors to disrupt survival pathways in tumor cells. Research efforts concentrate on identifying biological targets that regulate replication stress and ge

#10

Immutrin Series A

location_onCambridge, England

Biotechnology company developing next‑generation antibody therapies. The company focuses on creating next-generation antibody therapies. Their lead asset targets ATTR cardiomyopathy, a form of amyloidosis. The antibody is designed to selectively remove established amyloid fibrils.

#11

TympaHealth Series A

location_onLondon, England

Provider of an AI-based hearing health diagnosis device for medical professionals. The company has developed a portable hearing assessment device for the screening of the hearing abilities of a person. It has another wax removal tool along with the device that removes was from the ear using micro-suction technology. The device can analyze and diagnose the hearing capability of an individual and the data can be shared

#12

Centauri Therapeutics Series A

location_onKent, England

Developer of immunotherapeutics to treat infectious diseases. The company has proprietary Alphamer technology based on "programmable immunity"​ in which chemically synthesised molecules redirect naturally occurring antibodies to selected pathogens to fight the infections.